

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

James M. Robl et al.

Group Art Unit: 1632

Application Serial No. 09/685,061

Examiner: Thaian N. Ton

Filed: October 6, 2000

Title: EMBRYONIC OR STEM-LIKE CELL LINES PRODUCED BY CROSS SPECIES NUCLEAR
TRANSPLANTATION AND METHODS FOR ENHANCING EMBRYONIC DEVELOPMENT
BY GENETIC ALTERATION OF DONOR CELLS OR BY TISSUE CULTURE CONDITIONS

TECH CENTER 1600/2900

JAN 03 2001

RECEIVED

* * * * *

ELECTION

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Official Action [Restriction Requirement] dated November 29, 2001, Applicants elect without traverse Group I, Claims 1-25 and 31-50.

If the Examiner has any questions in connection with this election, he should contact the undersigned so that prosecution may be expedited.

In view of the foregoing, the claims are now believed to be in form for allowance, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

All objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Paul L. Sharer

Registration No. 36,004

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile
Date: December 31, 2001
Attorney Reference: 015837-0275492

Inventor(s): James M. Robl et al.

Appln. No.: 09 685,061


Series Code ↑

Serial No. ↑

Filed: October 6, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:



REPLY/AMENDMENT/LETTER

Group Art Unit 1632

Examiner: Thaian N. Ton

Atty. Dkt. P 0275492

M#

Client Ref

Appln. Title: Embryonic or Stem-Like Cell Lines
Produced by Cross Species Nuclear
Transplantation and Methods for
Enhancing Embryonic Development by
Genetic Alteration of Donor Cells or by
Tissue Culture Collections

Date: December 31, 2001

TECHNICAL STAFF
JAN 0 2001
DEC 31 2001

RECEIVED

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input checked="" type="checkbox"/> made previously		For B & C See <u>Required</u> <u>Separate</u> Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims				**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims				***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add							+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: December 29, 2001				<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo)	\$110/\$55 =	+ \$0			115/215
				(2 mos)	\$400/\$200 =				116/216
				(3 mos)	\$920/\$460 =				117/217
				(Usable only for ≤ 2mo.OA --- 4 mos)	\$1,440/\$720=				118/218
				(Usable only for 30 day/1mo.OA --- 5 mos)	\$1,960/\$980=				128/228
7. Enter any previous extension fee paid since above original due date and subtract							- \$0		
8. Extension Fee Attached							+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee							+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),							+ \$180	+ \$0	126
or if Rule 97(d) Request							+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)							+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)							x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)							+ \$740/370	+ \$0	1179/1279
14. Petition fee for							+ \$0.		
15. TOTAL FEE ENCLOSED =							\$0		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 015837 0275492

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Paul L. Sharer

Sig:

Reg. No. 36,004

Fax: (703) 905-2500

Tel: (703) 905-2219

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: BWM/kmh

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments